Neurocrine Biosciences, Inc.
NBIX
Market Cap$12.31B
Close$
$337.25
171.1% upside
Current Fair Value
171.1% upsideUndervalued by 171.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.31 Billion |
|---|---|
| Enterprise Value | $12.56 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $3.4 |
| Beta | 0.24 |
| Outstanding Shares | 99,700,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 40.55 |
|---|---|
| PEG | -49.58 |
| Price to Sales | 5.18 |
| Price to Book Ratio | 4.98 |
| Enterprise Value to Revenue | 5.21 |
| Enterprise Value to EBIT | 25.24 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Neurocrine Biosciences, Inc.
CEO: Kevin Gorman